Thomas Bures

Thomas Bures

Former Chief Financial OfficeratPalvella Therapeutics· In proxies 2022–2024

Pay in FY2024+29% from the year before · Palvella Therapeutics stock -17.6% the same year

Thomas Bures was paid $943.7K in FY2024 (Dec), up 29%. Palvella Therapeutics stock fell 17.6% that year.

Pay$100 in the stock at the end of FY21 → $4
Pay is from the Summary Compensation Table of each Palvella Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Palvella TherapeuticsPublic company · 4 yr
    • Former Chief Financial Officer2022 – Present · 4 yrStock in role -46%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?